Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Summary

A recent prospective observational clinical study conducted in an intensive care unit of a third level US university hospital showed that 94% of patients with ES and 50% of those with EC had an ARC for a duration of at least one day during the hospital stay.

Although there is currently a great deal of evidence describing ARC in various subgroups of critically ill patients, on the other hand there is little documentation regarding the effect that ARC can have on exposure to renally eliminated drugs.

Therefore, the aim of this study is to prospectively evaluate the proportion of plasma under-exposure to hydrophilic antimicrobials in patients with ES or EC and with ARC, in order to verify whether the recommended dosage regimens for these drugs are adequate for reaching the pharmacodynamic targets of therapeutic efficacy.

Conditions

• Therapeutic Drug Monitoring
• Subarachnoid Hemorrhage
• Intracerebral Hemorrhage

Interventions

DRUG

Piperacillin/tazobactam

Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration

DRUG

Meropenem

Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration

DRUG

Daptomycin

Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration

DRUG

Ceftobiprole

Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration

DRUG

Linezolid

Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration

DRUG

Vancomycin

Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration

DRUG

Fluconazol

Therapeutic drug monitoring (TDM) of this antifungal plasma concentration

DRUG

Acyclovir

Therapeutic drug monitoring (TDM) of this antiviral plasma concentration

DRUG

Gentamicins

Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration

DRUG

Amikacin

Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration

DRUG

Ganciclovir

Therapeutic drug monitoring (TDM) of this antiviral plasma concentration

Sponsors & Collaborators

• Azienda Sanitaria-Universitaria Integrata di Udine

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-10-01

Primary Completion

2021-10-31

Completion

2021-10-31

Countries

• Italy

Study Locations